{"name":"Università degli Studi di Ferrara","slug":"universit-degli-studi-di-ferrara","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Blood component B","genericName":"Blood component B","slug":"blood-component-b","indication":"Other","status":"marketed"},{"name":"Blood component A","genericName":"Blood component A","slug":"blood-component-a","indication":"Other","status":"marketed"},{"name":"Cristalloid administration","genericName":"Cristalloid administration","slug":"cristalloid-administration","indication":"Other","status":"phase_1"},{"name":"Mepolizumab 100 MG","genericName":"Mepolizumab 100 MG","slug":"mepolizumab-100-mg","indication":"Other","status":"marketed"},{"name":"bolus+infusion","genericName":"bolus+infusion","slug":"bolus-infusion","indication":"Other","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Bronchodilator Agents","genericName":"Bronchodilator Agents","slug":"bronchodilator-agents","indication":"Asthma","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"abciximab bolus only regimen","genericName":"abciximab bolus only regimen","slug":"abciximab-bolus-only-regimen","indication":"Acute coronary syndrome undergoing percutaneous coronary intervention","status":"marketed"}]}],"pipeline":[{"name":"Blood component B","genericName":"Blood component B","slug":"blood-component-b","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Bronchodilator Agents","genericName":"Bronchodilator Agents","slug":"bronchodilator-agents","phase":"marketed","mechanism":"Bronchodilator agents relax airway smooth muscle to increase airway diameter and improve airflow to the lungs.","indications":["Asthma","Chronic obstructive pulmonary disease (COPD)","Reversible airway obstruction"],"catalyst":""},{"name":"Blood component A","genericName":"Blood component A","slug":"blood-component-a","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Cristalloid administration","genericName":"Cristalloid administration","slug":"cristalloid-administration","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Mepolizumab 100 MG","genericName":"Mepolizumab 100 MG","slug":"mepolizumab-100-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"abciximab bolus only regimen","genericName":"abciximab bolus only regimen","slug":"abciximab-bolus-only-regimen","phase":"marketed","mechanism":"Abciximab is a chimeric monoclonal antibody that blocks the glycoprotein IIb/IIIa receptor on platelet surfaces, preventing platelet aggregation and thrombus formation.","indications":["Acute coronary syndrome undergoing percutaneous coronary intervention","Prevention of ischemic complications in high-risk patients undergoing coronary angioplasty"],"catalyst":""},{"name":"bolus+infusion","genericName":"bolus+infusion","slug":"bolus-infusion","phase":"marketed","mechanism":"A bolus-infusion regimen delivers a rapid initial dose followed by continuous or repeated slower administration to achieve and maintain therapeutic drug levels.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFBqazRLMXhrNmp4UzcyOEhUUk02ejNBajQybjJnZFFFcFl1ZTVwdjNiSVJJb2xwUF8xTmhiOWxPd1BGR3RxZmJpNXItTEdnQ1JCX1dGZFktWTUtclNC?oc=5","date":"2024-04-30","type":"pipeline","source":"EurekAlert!","summary":"A strategic vision for the future of Redox Medicine - EurekAlert!","headline":"A strategic vision for the future of Redox Medicine - EurekAlert!","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"marketed":6,"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}